You are here

  • Home
  • Archive
  • Volume 94, Issue 11
  • Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses

Citation Tools

Article menu
Multiple sclerosis
Short report
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Novak F, Bajwa HM, Coia JE, et al
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses
Journal of Neurology, Neurosurgery & Psychiatry 2023;94:934-937.